key: cord-0952527-zmpp1jze
authors: Culpan, Meftun; Keser, Ferhat; Acar, Hazal Cansu; Otunctemur, Alper; Kucuk, Eyup Veli; Erdem, Selcuk; Ozer, Murat; Sen, Ugur Tolga; Degirmenci, Enes; Ergul, Rifat; Atis, Ramazan Gokhan; Yildirim, Asif
title: Impact of delay in cystoscopic surveillance on recurrence and progression rates in patients with non‐muscle‐invasive bladder cancer during the COVID‐19 pandemic
date: 2021-06-22
journal: Int J Clin Pract
DOI: 10.1111/ijcp.14490
sha: 3a12f2f1157f339a8dac0ae51225406d2ed35d71
doc_id: 952527
cord_uid: zmpp1jze

PURPOSE: To evaluate the impact of delay in cystoscopic surveillance on recurrence and progression rates in non‐muscle‐invasive bladder cancer (NMIBC). MATERIALS AND METHODS: A total of 407 patients from four high‐volume centres with NMIBC that applied for follow‐up cystoscopy were included in our study prospectively. Patients’ demographics and previous tumour characteristics, the presence of tumour in follow‐up cystoscopy, the pathology results of the latest transurethral resection of bladder tumour (if tumour was detected) and the delay in cystoscopy time were recorded. Our primary outcomes were tumour recurrences detected by follow‐up cystoscopy and progression. Multivariate logistic regression analysis was performed using the possible factors identified with univariate analyses (P values ≤ .2). RESULTS: A total of 105 patients (25.8%) had tumour recurrence in follow‐up cystoscopy, and 20 (5.1%) of these patients had disease progression according to grade or stage. In multivariate analysis, the number of recurrences (OR: 1.307, P < .001) and the cystoscopy delay time (62‐147 days, OR: 2.424, P = .002; >147 days, OR: 4.883, P < .001) were significant risk factors for tumour recurrence on follow‐up cystoscopy; the number of recurrences (OR: 1.255, P = .024) and cystoscopy delay time (>90 days, OR: 6.704, P = .002) were significant risk factors for tumour progression. CONCLUSIONS: This study showed that a 2‐5 months of delay in follow‐up cystoscopy increases the risk of recurrence by 2.4‐fold, and delay in cystoscopy for more than 3 months increases the probability of progression by 6.7‐fold. We suggest that cystoscopic surveillance should be done during the COVID‐19 pandemic according to the schedule set by relevant guidelines.

diagnosis, risk-group stratification must be done, and surveillance or treatment modalities must be decided for each risk group. 4 After complete resection of the bladder tumour, risk-group stratification, and, if necessary, appropriate intravesical therapy, patients must undergo an established surveillance schedule with cystoscopy.

According to the European Association of Urology (EAU) guidelines, primary, solitary, Ta, low-grade and <3-cm tumours without CIS are defined as low-risk tumours. T1, high-grade, CIS or multiple, recurrent and large Ta low-grade tumours are defined as high-risk tumours. Other tumours that are not classified as low or high risk must be defined as intermediate-risk tumours. In the surveillance protocol, patients with high-grade tumours must undergo a follow-up cystoscopy every 3 months in the first 2 years, every 6 months in the next 3 years, and every year after 5 years. Patients with lowrisk tumours must undergo follow-up cystoscopy at 3 months after resection; if negative, they must undergo subsequent cystoscopy 9 months later and then yearly. Lastly, patients with intermediaterisk tumours must undergo an individualized surveillance schedule with frequencies that are between those established for patients with low-and high-risk tumours. 5 Despite widespread usage, these suggestions are based mostly on expert opinion and not on a great amount of evidence. A previous study reported that the adjusted frequency of follow-up cystoscopies ranged from 4.6 to 6.0 over 2 years per high-risk NMIBC patient in the United States. 6 This study showed that many of the patients with high-risk NMIBC underwent fewer cystoscopies than suggested. Actually, it is not known how much a delay in cystoscopy surveillance will adversely affect oncological results.

Since early 2020, the coronavirus disease of 2019 (COVID-19) has been spreading all over the world, and the World Health Organization (WHO) declared a pandemic on 11 March 2020. COVID-19 has had a devastating effect on healthcare systems.

Many changes had to be taken in the provision of healthcare services because of the medical and economic burden that COVID-19 brought to the healthcare system. Many medical doctors had to take part in the care of patients with COVID-19, not their specialty, and delays were experienced in the diagnosis and treatment of many diseases other than COVID-19, including cancer. All healthcare institutions and healthcare workers focused on the pandemic and patients with COVID-19. As a result of this situation, many patients with NMIBC could not undergo a follow-up cystoscopy on time, and serious delays were experienced.

In this study, we aimed to evaluate the impact of delay in cystoscopic surveillance on recurrence and progression rates after TUR-BT.

This observational prospective cohort study was conducted between June-September 2020, after institutional ethical committee approval. Informed consent was obtained from all patients when they were enrolled. Patients with NMIBC who applied for follow-up cystoscopy after the pandemic restrictions were lifted were included in our study. Patients with MIBC, no history of bladder tumour diagnosis, incomplete resection at previous TUR-BT and unknown bladder tumour pathology results before or after the follow-up cystoscopy were excluded from the study. A total of 407 patients from four high-volume centres were included in our study.

Patients with NMIBC who had applied for follow-up cystoscopy underwent the procedure with rigid or flexible cystoscope under local or general anaesthesia. The EAU surveillance schedule described above was used for timing the follow-up cystoscopies. The presence of a tumour in follow-up cystoscopy was defined as "recurrence." If a recurrence was detected, the pathological characteristics of sequential TUR-BT were noted. Our primary outcomes were tumour recurrences and progression detected by follow-up cystoscopy. Any advancement in grade (low to high grade) or stage (Ta to T1 or any T2) in TUR-BT, which was performed after the follow-up cystoscopy, was accepted as "progression. 

• This study showed the negative impact of cystoscopy delay in patients with non-muscle-invasive bladder cancer and found that a delay of more than 3 months in the time of cystoscopy causes a significant increase in progression rates.

appropriate. Cystoscopy delay time cut-offs for recurrence and progression were assessed by using Receiver Operating Characteristic (ROC) analysis. Multivariate logistic regression analysis was performed by using the possible factors identified with univariate analyses (P values ≤ .2). To avoid possible multicollinearity, only one of the highly correlated variables, the one with a high contribution to the model, was included in the multivariable logistic regression analysis. Results were presented as Odds Ratio (OR) and 95% Confidence Intervals (95% CI). Significance level was accepted as P < .05. risk tumours, the number of recurrences was also an independent risk factor for tumour recurrences (Table 3) .

Age, sex and CCI were comparable between the two groups with or without progression. In univariate analysis, there was a significant difference in number of recurrences (P < .001), follow-up cystoscopy delay time (P < .001) and highest TUR grade (P = .020) and EAU risk group (P = .024) between the groups with and without tumour progression ( 

showed that a 2-5 months of delay in follow-up cystoscopy increases the risk of recurrence by 2.4-fold, and a delay in cystoscopy for more than 3 months increases the probability of progression by 6.7-fold.

Subgroup analysis revealed that the increased risk for recurrence caused by the delay in cystoscopy was valid in all three risk groups.

In intermediate-and high-risk patients, the number of recurrences was also the significant predictor of recurrence.

Patients with low-risk NMIBC have an approximately 30% recurrence rate in the 5-year follow-up, but, despite high recurrence rates, they have progression rates under 2%. 3 Because of the very low progression rates, active surveillance protocols have been studied in this patient cohort. 9 Hernandez et al designed a prospective study and included patients with NMIBC in an active surveillance program. They followed up 186 patients with a median of 72 months and stated that only 4 (2%) patients had progression to MIBC, but all of them previously had T1 disease. 10 Similarly, Hurle et al reported that there was no progression to MIBC in their active surveillance study, which included 122 Ta-T1a patients. 11 Because of these findings, many experts state that cystoscopy follow-ups may be delayed in low-risk NMIBC. In our study, we found that delayed follow-up cystoscopy in low-risk disease significantly increases recurrence rates. However, in our cohort, there were no patients with low-risk disease that showed progression.

In contrast with the low-risk diseases, high-risk NMIBC has high progression rates up to 45%. 3 Because of the high recurrence and especially on account of the progression rates, many urological associations and societies suggest not to defer follow-up cystoscopy. 12 In routine practice, we perform follow-up cystoscopy every 3 months in the first 2 years to detect recurrences at a more curable stage. In a recent study, Rezaee et al investigated the impact of low (1-5 cystoscopies in the first 2 years) versus high (6 or more cystoscopies in the first 2 years) intensity follow-up cystoscopy in patients with NMIBC.

They reported that patients with low-intensity surveillance underwent fewer TURs (37 vs 99 per 100 person-years; P < .001). They did not, however, experience an increased risk of progression. 13 In contrast to this study, we found a significant risk increase in progression rates with a 3-month delay in NMIBC. Consequently, we support the recommendations not to delay follow-up cystoscopy in patients with NMIBC.

To our knowledge, this is the first study investigating the impact of delay in follow-up cystoscopy on oncological outcomes. analysis. We could not analyse the impact of delay in cystoscopy for cancer-specific or overall survival. However, we think that this study provides evidence-based data on not delaying cystoscopy, these days when the pandemic is still ongoing; therefore, we did not prolong our follow-up for cancer specific of overall survival analyses.

In our analysis, it is demonstrated that a 2-5 months of delay in follow-up cystoscopy increases the risk of recurrence by 2.4-fold, and delay in cystoscopy for more than 3 months increases the probability of progression by 6.7-fold. As a consequence of these findings, we suggest that cystoscopic surveillance for NMIBC should be done in as timely a manner as possible according to the relevant guidelines during the COVID-19 pandemic.

All authors declare that they have no conflict of interest.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. 

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available because of privacy or ethical restrictions.

https://orcid.org/0000-0001-8573-1192

Selcuk Erdem https://orcid.org/0000-0002-3514-1394

Cancer statistics, 2020

Platinum priority-reviewbladder cancer epidemiology and risk factors of urothelial bladder cancer

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials

Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel

EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam

Extent of risk-aligned surveillance for cancer recurrence among patients with early-stage bladder cancer

Risks from deferring treatment for genitourinary cancers: a collaborative review to aid triage and management during the COVID-19 pandemic

Delaying cancer cases in urology during COVID-19: review of the literature

Active surveillance for non-muscle invasive bladder cancer

Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer

Active surveillance for low-risk Non-Muscle Invasive Bladder Cancer (NMIBC): a confirmatory and resource consumption study from Bladder cancer Italian Active Surveillance (BIAS) project

Forecasting the future of urology practice: a comprehensive review of the recommendations by International and European Associations on priority procedures during the COVID-19 pandemic

The impact of low-versus highintensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC)

Delay and survival in bladder cancer

Predictors of delay to cystoscopy and adequacy of investigations in patients with haematuria

Impact of delay in cystoscopic surveillance on recurrence and progression rates in patients with non-muscle-invasive bladder cancer during the COVID-19 pandemic